207 related articles for article (PubMed ID: 18640038)
1. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
DiMauro EF; Buchanan JL; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Janosky B; Lee JH; Li X; Martin MW; Tomlinson SA; White RD; Zheng XM; Patel VF; Fremeau RT
Bioorg Med Chem Lett; 2008 Aug; 18(15):4267-74. PubMed ID: 18640038
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
[TBL] [Abstract][Full Text] [Related]
3. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.
Omura H; Kawai M; Shima A; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A; Iwata H; Ando K
Bioorg Med Chem Lett; 2008 Jun; 18(11):3310-4. PubMed ID: 18440813
[TBL] [Abstract][Full Text] [Related]
4. 2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.
Muraglia E; Altamura S; Branca D; Cecchetti O; Ferrigno F; Orsale MV; Palumbi MC; Rowley M; Scarpelli R; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2008 Dec; 18(23):6083-7. PubMed ID: 18930398
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
6. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
7. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.
Ryckmans T; Edwards MP; Horne VA; Correia AM; Owen DR; Thompson LR; Tran I; Tutt MF; Young T
Bioorg Med Chem Lett; 2009 Aug; 19(15):4406-9. PubMed ID: 19500981
[TBL] [Abstract][Full Text] [Related]
8. Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Sellitto I; Le Bourdonnec B; Worm K; Goodman A; Savolainen MA; Chu GH; Ajello CW; Saeui CT; Leister LK; Cassel JA; Dehaven RN; Labuda CJ; Koblish M; Little PJ; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2010 Jan; 20(1):387-91. PubMed ID: 19919895
[TBL] [Abstract][Full Text] [Related]
9. Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity.
Ermann M; Riether D; Walker ER; Mushi IF; Jenkins JE; Noya-Marino B; Brewer ML; Taylor MG; Amouzegh P; East SP; Dymock BW; Gemkow MJ; Kahrs AF; Ebneth A; Löbbe S; O'Shea K; Shih DT; Thomson D
Bioorg Med Chem Lett; 2008 Mar; 18(5):1725-9. PubMed ID: 18255291
[TBL] [Abstract][Full Text] [Related]
10. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A
J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967
[TBL] [Abstract][Full Text] [Related]
11. Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic properties.
Marx IE; DiMauro EF; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Human J; Lee JH; Li X; Martin MW; White RD; Fremeau RT; Patel VF
Bioorg Med Chem Lett; 2009 Jan; 19(1):31-5. PubMed ID: 19062274
[TBL] [Abstract][Full Text] [Related]
12. 6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
Diaz P; Phatak SS; Xu J; Astruc-Diaz F; Cavasotto CN; Naguib M
J Med Chem; 2009 Jan; 52(2):433-44. PubMed ID: 19115816
[TBL] [Abstract][Full Text] [Related]
13. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
Watson C; Owen DR; Harding D; Kon-I K; Lewis ML; Mason HJ; Matsumizu M; Mukaiyama T; Rodriguez-Lens M; Shima A; Takeuchi M; Tran I; Young T
Bioorg Med Chem Lett; 2011 Jul; 21(14):4284-7. PubMed ID: 21669533
[TBL] [Abstract][Full Text] [Related]
14. 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability.
Riether D; Wu L; Cirillo PF; Berry A; Walker ER; Ermann M; Noya-Marino B; Jenkins JE; Albaugh D; Albrecht C; Fisher M; Gemkow MJ; Grbic H; Löbbe S; Möller C; O'Shea K; Sauer A; Shih DT; Thomson DS
Bioorg Med Chem Lett; 2011 Apr; 21(7):2011-6. PubMed ID: 21354795
[TBL] [Abstract][Full Text] [Related]
15. 2-Amino-5-aryl-pyridines as selective CB2 agonists: synthesis and investigation of structure-activity relationships.
Gleave RJ; Beswick PJ; Brown AJ; Giblin GM; Haslam CP; Livermore D; Moses A; Nicholson NH; Page LW; Slingsby B; Swarbrick ME
Bioorg Med Chem Lett; 2009 Dec; 19(23):6578-81. PubMed ID: 19864133
[TBL] [Abstract][Full Text] [Related]
16. 2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase).
Warmus JS; Flamme C; Zhang LY; Barrett S; Bridges A; Chen H; Gowan R; Kaufman M; Sebolt-Leopold J; Leopold W; Merriman R; Ohren J; Pavlovsky A; Przybranowski S; Tecle H; Valik H; Whitehead C; Zhang E
Bioorg Med Chem Lett; 2008 Dec; 18(23):6171-4. PubMed ID: 18951019
[TBL] [Abstract][Full Text] [Related]
17. Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters.
Zindell R; Walker ER; Scott J; Amouzegh P; Wu L; Ermann M; Thomson D; Fisher MB; Fullenwider CL; Grbic H; Kaplita P; Linehan B; Patel M; Patel M; Löbbe S; Block S; Albrecht C; Gemkow MJ; Shih DT; Riether D
Bioorg Med Chem Lett; 2011 Jul; 21(14):4276-80. PubMed ID: 21689933
[TBL] [Abstract][Full Text] [Related]
18. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
[TBL] [Abstract][Full Text] [Related]
19. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J
J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726
[TBL] [Abstract][Full Text] [Related]
20. N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Ohta H; Ishizaka T; Tatsuzuki M; Yoshinaga M; Iida I; Tomishima Y; Toda Y; Saito S
Bioorg Med Chem Lett; 2007 Nov; 17(22):6299-304. PubMed ID: 17884496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
